Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 5/2018

05.03.2018 | Original Article – Clinical Oncology

Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4–10 ng/ml?

verfasst von: Ning Xu, Yu-Peng Wu, Dong-Ning Chen, Zhi-Bin Ke, Hai Cai, Yong Wei, Qing-Shui Zheng, Jin-Bei Huang, Xiao-Dong Li, Xue-Yi Xue

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To explore the value of Prostate Imaging Reporting and Data System Version 2 (PI-RADS v2) for predicting prostate biopsy results in patients with prostate specific antigen (PSA) levels of 4–10 ng/ml.

Methods

We retrospectively reviewed multi-parameter magnetic resonance images from 528 patients with PSA levels of 4–10 ng/ml who underwent transrectal ultrasound-guided prostate biopsies between May 2015 and May 2017. Among them, 137 were diagnosed with prostate cancer (PCa), and we further subdivided them according to pathological results into the significant PCa (S-PCa) and insignificant significant PCa (Ins-PCa) groups (121 cases were defined by surgical pathological specimen and 16 by biopsy). Age, PSA, percent free PSA, PSA density (PSAD), prostate volume (PV), and PI-RADS score were collected. Logistic regression analysis was performed to determine predictors of pathological results. Receiver operating characteristic curves were constructed to analyze the diagnostic value of PI-RADS v2 in PCa.

Results

Multivariate analysis indicated that age, PV, percent free PSA, and PI-RADS score were independent predictors of biopsy findings, while only PI-RADS score was an independent predictor of S-PCa (P < 0.05). The areas under the receiver operating characteristic curve for diagnosing PCa with respect to age, PV, percent free PSA, and PI-RADS score were 0.570, 0.430, 0.589 and 0.836, respectively. The area under the curve for diagnosing S-PCa with respect to PI-RADS score was 0.732. A PI-RADS score of 3 was the best cutoff for predicting PCa, and 4 was the best cutoff for predicting S-PCa. Thus, 92.8% of patients with PI-RADS scores of 1–2 would have avoided biopsy, but at the cost of missing 2.2% of the potential PCa cases. Similarly, 83.82% of patients with a PI-RADS score ≤ 3 would have avoided biopsy, but at the cost of missing 3.3% of the potential S-PCa cases.

Conclusions

PI-RADS v2 could be used to reduce unnecessary prostate biopsies in patients with PSA levels of 4–10 ng/ml.
Literatur
Zurück zum Zitat Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, Collaco-Moraes Y, Ward K, Hindley RG, Freeman A, Kirkham AP, Oldroyd R, Parker C, Emberton M, group Ps (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389:815–822. https://doi.org/10.1016/S0140-6736(16)32401-1 CrossRefPubMed Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, Collaco-Moraes Y, Ward K, Hindley RG, Freeman A, Kirkham AP, Oldroyd R, Parker C, Emberton M, group Ps (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389:815–822. https://​doi.​org/​10.​1016/​S0140-6736(16)32401-1 CrossRefPubMed
Zurück zum Zitat Chen R, Huang Y, Cai X, Xie L, He D, Zhou L, Xu C, Gao X, Ren S, Wang F, Ma L, Wei Q, Yin C, Tian Y, Sun Z, Fu Q, Ding Q, Zheng J, Ye Z, Ye D, Xu D, Hou J, Xu K, Yuan J, Gao X, Liu C, Pan T, Sun Y (2015a) Age-specific cutoff value for the application of percent free prostate-specific antigen (PSA) in Chinese men with serum PSA levels of 4.0–10.0 ng/ml. PLoS One 10:e0130308. https://doi.org/10.1371/journal.pone.0130308 CrossRefPubMedPubMedCentral Chen R, Huang Y, Cai X, Xie L, He D, Zhou L, Xu C, Gao X, Ren S, Wang F, Ma L, Wei Q, Yin C, Tian Y, Sun Z, Fu Q, Ding Q, Zheng J, Ye Z, Ye D, Xu D, Hou J, Xu K, Yuan J, Gao X, Liu C, Pan T, Sun Y (2015a) Age-specific cutoff value for the application of percent free prostate-specific antigen (PSA) in Chinese men with serum PSA levels of 4.0–10.0 ng/ml. PLoS One 10:e0130308. https://​doi.​org/​10.​1371/​journal.​pone.​0130308 CrossRefPubMedPubMedCentral
Zurück zum Zitat Chen R, Zhou LQ, Cai XB, Xie LP, Huang YR, He DL, Gao X, Xu CL, Ding Q, Wei Q, Yin CJ, Ren SC, Wang FB, Tian Y, Sun ZQ, Fu Q, Ma LL, Zheng JH, Ye ZQ, Ye DW, Xu DF, Hou JQ, Xu KX, Yuan JL, Gao X, Liu CX, Pan TJ, Sun YH, Chinese Prostate Cancer C (2015b) Percent free prostate-specific antigen is effective to predict prostate biopsy outcome in Chinese men with prostate-specific antigen between 10.1 and 20.0 ng ml(−1). Asian J Androl 17:1017–1021. https://doi.org/10.4103/1008-682X.150846 CrossRefPubMedPubMedCentral Chen R, Zhou LQ, Cai XB, Xie LP, Huang YR, He DL, Gao X, Xu CL, Ding Q, Wei Q, Yin CJ, Ren SC, Wang FB, Tian Y, Sun ZQ, Fu Q, Ma LL, Zheng JH, Ye ZQ, Ye DW, Xu DF, Hou JQ, Xu KX, Yuan JL, Gao X, Liu CX, Pan TJ, Sun YH, Chinese Prostate Cancer C (2015b) Percent free prostate-specific antigen is effective to predict prostate biopsy outcome in Chinese men with prostate-specific antigen between 10.1 and 20.0 ng ml(−1). Asian J Androl 17:1017–1021. https://​doi.​org/​10.​4103/​1008-682X.​150846 CrossRefPubMedPubMedCentral
Zurück zum Zitat Fang S, Xu C, Zhang Y, Xue C, Yang C, Bi H, Qian X, Wu M, Ji K, Zhao Y, Wang Y, Liu H, Xing X (2016) Umbilical cord-derived mesenchymal stem cell-derived exosomal microRNAs suppress myofibroblast differentiation by inhibiting the transforming growth factor-beta/SMAD2 pathway during wound healing stem. Cells Transl Med 5:1425–1439. https://doi.org/10.5966/sctm.2015-0367 CrossRef Fang S, Xu C, Zhang Y, Xue C, Yang C, Bi H, Qian X, Wu M, Ji K, Zhao Y, Wang Y, Liu H, Xing X (2016) Umbilical cord-derived mesenchymal stem cell-derived exosomal microRNAs suppress myofibroblast differentiation by inhibiting the transforming growth factor-beta/SMAD2 pathway during wound healing stem. Cells Transl Med 5:1425–1439. https://​doi.​org/​10.​5966/​sctm.​2015-0367 CrossRef
Zurück zum Zitat Huang M, Lin Y, Xu A, Uhlman M, Deng X, Lin X, Wu S, Diao P, Xie K, Tang P (2014) Percent free prostate-specific antigen does not improve the effectiveness of prostate cancer detection in Chinese men with a prostate-specific antigen of 2.5–20.0 ng/ml: a multicenter study. Med Oncol 31:925. https://doi.org/10.1007/s12032-014-0925-4 CrossRefPubMed Huang M, Lin Y, Xu A, Uhlman M, Deng X, Lin X, Wu S, Diao P, Xie K, Tang P (2014) Percent free prostate-specific antigen does not improve the effectiveness of prostate cancer detection in Chinese men with a prostate-specific antigen of 2.5–20.0 ng/ml: a multicenter study. Med Oncol 31:925. https://​doi.​org/​10.​1007/​s12032-014-0925-4 CrossRefPubMed
Zurück zum Zitat Lodeta B, Benko G, Car S, Filipan Z, Stajcar D, Dujmovic T (2009) Prostate specific antigen density can help avoid unnecessary prostate biopsies at prostate specific antigen range of 4–10 ng/ml. Acta Clin Croat 48:153–155PubMed Lodeta B, Benko G, Car S, Filipan Z, Stajcar D, Dujmovic T (2009) Prostate specific antigen density can help avoid unnecessary prostate biopsies at prostate specific antigen range of 4–10 ng/ml. Acta Clin Croat 48:153–155PubMed
Zurück zum Zitat Moldovan PC, Van den Broeck T, Sylvester R, Marconi L, Bellmunt J, van den Bergh RCN, Bolla M, Briers E, Cumberbatch MG, Fossati N, Gross T, Henry AM, Joniau S, van der Kwast TH, Matveev VB, van der Poel HG, De Santis M, Schoots IG, Wiegel T, Yuan CY, Cornford P, Mottet N, Lam TB, Rouviere O (2017) What is the negative predictive value of multiparametric magnetic resonance imaging in excluding prostate cancer at biopsy? A systematic review and meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. Eur Urol 72:250–266. https://doi.org/10.1016/j.eururo.2017.02.026 CrossRefPubMed Moldovan PC, Van den Broeck T, Sylvester R, Marconi L, Bellmunt J, van den Bergh RCN, Bolla M, Briers E, Cumberbatch MG, Fossati N, Gross T, Henry AM, Joniau S, van der Kwast TH, Matveev VB, van der Poel HG, De Santis M, Schoots IG, Wiegel T, Yuan CY, Cornford P, Mottet N, Lam TB, Rouviere O (2017) What is the negative predictive value of multiparametric magnetic resonance imaging in excluding prostate cancer at biopsy? A systematic review and meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. Eur Urol 72:250–266. https://​doi.​org/​10.​1016/​j.​eururo.​2017.​02.​026 CrossRefPubMed
Zurück zum Zitat Porpiglia F, Manfredi M, Mele F, Cossu M, Bollito E, Veltri A, Cirillo S, Regge D, Faletti R, Passera R, Fiori C, De Luca S (2017) Diagnostic pathway with multiparametric magnetic resonance imaging versus standard pathway: results from a randomized prospective study in biopsy-naive patients with suspected prostate cancer. Eur Urol 72:282–288. https://doi.org/10.1016/j.eururo.2016.08.041 CrossRefPubMed Porpiglia F, Manfredi M, Mele F, Cossu M, Bollito E, Veltri A, Cirillo S, Regge D, Faletti R, Passera R, Fiori C, De Luca S (2017) Diagnostic pathway with multiparametric magnetic resonance imaging versus standard pathway: results from a randomized prospective study in biopsy-naive patients with suspected prostate cancer. Eur Urol 72:282–288. https://​doi.​org/​10.​1016/​j.​eururo.​2016.​08.​041 CrossRefPubMed
Zurück zum Zitat Pourmand G, Allameh F, Mohammad K, Dehghani S, Pourmand B, Mehrsai A, Hosseini SH (2012) Prostate cancer predicting factors: a preliminary report from Tehran. Urol J 9:667–672PubMed Pourmand G, Allameh F, Mohammad K, Dehghani S, Pourmand B, Mehrsai A, Hosseini SH (2012) Prostate cancer predicting factors: a preliminary report from Tehran. Urol J 9:667–672PubMed
Zurück zum Zitat Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Maattanen L, Lilja H, Denis LJ, Recker F, Paez A, Bangma CH, Carlsson S, Puliti D, Villers A, Rebillard X, Hakama M, Stenman UH, Kujala P, Taari K, Aus G, Huber A, van der Kwast TH, van Schaik RH, de Koning HJ, Moss SM, Auvinen A, Investigators E (2014) Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 384:2027–2035. https://doi.org/10.1016/S0140-6736(14)60525-0 CrossRefPubMedPubMedCentral Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Maattanen L, Lilja H, Denis LJ, Recker F, Paez A, Bangma CH, Carlsson S, Puliti D, Villers A, Rebillard X, Hakama M, Stenman UH, Kujala P, Taari K, Aus G, Huber A, van der Kwast TH, van Schaik RH, de Koning HJ, Moss SM, Auvinen A, Investigators E (2014) Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 384:2027–2035. https://​doi.​org/​10.​1016/​S0140-6736(14)60525-0 CrossRefPubMedPubMedCentral
Zurück zum Zitat Tomaskovic I, Ulamec M, Tomic M, Pezelj I, Grubisic I, Kruslin B (2015) Validation of epstein biopsy criteria for insignificant prostate cancer in contemporary cohort of croatian Patients. Coll Antropol 39:709–711PubMed Tomaskovic I, Ulamec M, Tomic M, Pezelj I, Grubisic I, Kruslin B (2015) Validation of epstein biopsy criteria for insignificant prostate cancer in contemporary cohort of croatian Patients. Coll Antropol 39:709–711PubMed
Zurück zum Zitat Washino S, Okochi T, Saito K, Konishi T, Hirai M, Kobayashi Y, Miyagawa T (2017) Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naive patients. BJU Int 119:225–233. https://doi.org/10.1111/bju.13465 CrossRefPubMed Washino S, Okochi T, Saito K, Konishi T, Hirai M, Kobayashi Y, Miyagawa T (2017) Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naive patients. BJU Int 119:225–233. https://​doi.​org/​10.​1111/​bju.​13465 CrossRefPubMed
Zurück zum Zitat Xu N, Xue XY, Li XD, Wei Y, Lin N (2014) Meperidine relieves pain during transrectal ultrasound-guided prostate biopsy. Saudi Med J 35:454–459PubMed Xu N, Xue XY, Li XD, Wei Y, Lin N (2014) Meperidine relieves pain during transrectal ultrasound-guided prostate biopsy. Saudi Med J 35:454–459PubMed
Metadaten
Titel
Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4–10 ng/ml?
verfasst von
Ning Xu
Yu-Peng Wu
Dong-Ning Chen
Zhi-Bin Ke
Hai Cai
Yong Wei
Qing-Shui Zheng
Jin-Bei Huang
Xiao-Dong Li
Xue-Yi Xue
Publikationsdatum
05.03.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 5/2018
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-018-2616-6

Weitere Artikel der Ausgabe 5/2018

Journal of Cancer Research and Clinical Oncology 5/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.